Company A.P. Pharma, Inc. OTC Bulletin Board

Equities

APPA

US00202J2033

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

24/06	Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to S&P Biotechnology Select Industry Index	CI
12/06	Connect Biopharma Names New Chief Executive, Chair	MT

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

USD in Million	2022	Weight	2023	Weight	Delta
Therapeutic Innovations 100.0 %	108	100.0 %	127	100.0 %	+17.99%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	108	100.0 %	127	100.0 %	+17.99%

Managers	Title	Age	Since
Craig Collard CEO	Chief Executive Officer	58	21/23/21
Ira Duarte DFI	Director of Finance/CFO	55	16/23/16
Chris Storgard CTO	Chief Tech/Sci/R&D Officer	58	01/18/01
Thomas B. Ottoboni CTO	Chief Tech/Sci/R&D Officer	65	30/12/30
John C. Arthur PRN	Corporate Officer/Principal	58	01/17/01
Sean T. Ristine HRO	Human Resources Officer	54	01/14/01
William Forbes PRN	Corporate Officer/Principal	62	06/23/06

Members of the board	Title	Age	Since
Craig Collard CEO	Chief Executive Officer	58	21/23/21
Susan Rodriguez BRD	Director/Board Member	60	20/21/20
Craig Johnson BRD	Director/Board Member	62	13/14/13
Christian Waage BRD	Director/Board Member	57	22/16/22
Adam Morgan CHM	Chairman	45	21/23/21
Sharmila Dissanaike BRD	Director/Board Member	49	20/21/20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	150,653,158	149,597,060 ( 99.30 %)	0	99.30 %

Name	Equities	%	Valuation
Rubric Capital Management LP 17.73 %	26,713,503	17.73 %	99 M $
OrbiMed Advisors Private Equity 6.712 %	10,111,550	6.712 %	37 M $
Vanguard Fiduciary Trust Co. 5.386 %	8,114,716	5.386 %	30 M $
Velan Capital Investment Management LP 4.638 %	6,986,744	4.638 %	26 M $
BlackRock Advisors LLC 4.634 %	6,980,757	4.634 %	26 M $
Fiduciary Trust Company International 4.231 %	6,374,584	4.231 %	24 M $
Tejara Capital Ltd. 2.928 %	4,411,567	2.928 %	16 M $
Palisade Capital Management LP 2.477 %	3,732,241	2.477 %	14 M $
Millennium Management LLC 2.102 %	3,167,286	2.102 %	12 M $
Adage Capital Partners GP LLC 1.932 %	2,910,011	1.932 %	11 M $

Heron Therapeutics, Inc.

4242 Campus Point Court Suite 200

92121, San Diego

+858 251 4400

http://www.herontx.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+23.13%	46.93B
LONZA GROUP AG	+36.98%	39.08B
IQVIA HOLDINGS INC.	-8.73%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+28.09%	31.01B
CELLTRION, INC.	-12.26%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.57%	25.88B
MEDPACE HOLDINGS, INC.	+32.23%	12.53B
BIO-TECHNE CORPORATION	-6.56%	11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.56%	10.65B

Other Biotechnology & Medical Research